All Outputs (27)

Intratumor microbiota as a novel potential prognostic indicator in mesothelioma (2023)
Journal Article
Pentimalli, F., Krstic- Demonacos, M., Costa, C., Mutti, L., & Bakker, E. (2023). Intratumor microbiota as a novel potential prognostic indicator in mesothelioma. Frontiers in Immunology, 14, https://doi.org/10.3389/fimmu.2023.1129513

Introduction: Despite increased attention on immunotherapy, primarily immune checkpoint blockade, as a therapeutic approach for mesothelioma (MMe), its efficacy and tolerability remain questioned. One potential explanation for different responses to... Read More about Intratumor microbiota as a novel potential prognostic indicator in mesothelioma.

Elimination of Off-Target Effect by Chemical Modification of 5'-End of Small Interfering RNA (2022)
Journal Article

In this study, the efficiency of RNA interference of small interfering RNAs (siRNAs) bearing 5′-O-methyl-2′-deoxythymidine (X) and 5′-amino-2′, 5′-dideoxythymidine (Z) at the 5′-end of the sense strand and the antisense strand of siRNA was investigat... Read More about Elimination of Off-Target Effect by Chemical Modification of 5'-End of Small Interfering RNA.

Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma (2022)
Journal Article

Importance: Some recently proposed frontline therapies for malignant pleural mesothelioma (MPM) are very costly, yet their impact on quality of life and overall survival of these patients remains arguable. Given the high social toll of this aggressiv... Read More about Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma.

Protein disulfide isomerase A1‑associated pathways in the development of stratified breast cancer therapies (2022)
Journal Article
Bakker, E., Fujii, M., Krstic‑Demonacos, M., Demonacos, C., & Alhammad, R. (2022). Protein disulfide isomerase A1‑associated pathways in the development of stratified breast cancer therapies. International Journal of Oncology, 60(2), 16. https://doi.org/10.3892/ijo.2022.5306

The oxidoreductase protein disulfide isomerase A1 (PDIA1) functions as a cofactor for many transcription factors including estrogen receptor α (ERα), nuclear factor (NF)‑κB, nuclear factor erythroid 2‑like 2 (NRF2) and regulates the protein stability... Read More about Protein disulfide isomerase A1‑associated pathways in the development of stratified breast cancer therapies.

Evaluation of the role of p53 tumour suppressor posttranslational modifications and TTC5 cofactor in lung cancer (2021)
Journal Article

Mutations in the p53 tumor suppressor are found in over 50% of cancers. p53 function is controlled through posttranslational modifications and cofactor interactions. In this study, we investigated the posttranslationally modified p53, including p53 a... Read More about Evaluation of the role of p53 tumour suppressor posttranslational modifications and TTC5 cofactor in lung cancer.

Is there already a need of reckoning on cancer immunotherapy? (2021)
Journal Article
Correale, P., Pentimalli, F., Baglio, G., Krstic- Demonacos, M., Saladino, R., Giordano, A., & Mutti, L. (2021). Is there already a need of reckoning on cancer immunotherapy?. Frontiers in Pharmacology, 12, 638279. https://doi.org/10.3389/fphar.2021.638279

Circular and linear : a tale of aptamer selection for the activation of SIRT1 to induce death in cancer cells (2020)
Journal Article
Al-Sudani, B., Ragazzon-Smith, A., Aziz, A., Alansari, R., Ferry, N., Krstic- Demonacos, M., & Ragazzon, P. (2020). Circular and linear : a tale of aptamer selection for the activation of SIRT1 to induce death in cancer cells. RSC Advances, 10(73), 45008-45018. https://doi.org/10.1039/D0RA07857C

It is a challenge to select the right target to treat conditions without affecting non-diseased cells. Cancer belongs to the top 10 causes of death in the world and it remains difficult to treat. Amongst cancer emerging targets, silent information re... Read More about Circular and linear : a tale of aptamer selection for the activation of SIRT1 to induce death in cancer cells.

Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state (2020)
Journal Article

Oxidoreductase protein disulphide isomerases (PDI) are involved in the regulation of a variety of biological processes including the modulation of endoplasmic reticulum (ER) stress, unfolded protein response (UPR), ER‑mitochondria communication and t... Read More about Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state.

Endoplasmic reticulum stress, unfolded protein response and autophagy contribute to resistance to glucocorticoid treatment in human acute lymphoblastic leukaemia cells (2020)
Journal Article

Acute lymphoblastic leukaemia (ALL) is the most frequent childhood cancer and, although it is highly treatable, resistance to therapy, toxicity and side effects remain challenging. The synthetic glucocorticoid (GC) dexamethasone (Dex) is commonly use... Read More about Endoplasmic reticulum stress, unfolded protein response and autophagy contribute to resistance to glucocorticoid treatment in human acute lymphoblastic leukaemia cells.

Telomerase inhibition, Telomere attrition and proliferation arrest of cancer cells induced by Phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT (2020)
Journal Article
Diala, I., Shiohama, Y., Fujita, T., Demonacos, C., Krstic- Demonacos, M., Di Leva, G., & Fujii, N. (2020). Telomerase inhibition, Telomere attrition and proliferation arrest of cancer cells induced by Phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT. Nucleosides, Nucleotides and Nucleic Acids, 39(1-3), 407-425. https://doi.org/10.1080/15257770.2020.1713357

Telomerase activity has been regarded as a critical step in cellular immortalization and carcinogenesis and because of this, regulation of telomerase represents an attractive target for anti-tumor specific therapeutics. Recently, one avenue of cancer... Read More about Telomerase inhibition, Telomere attrition and proliferation arrest of cancer cells induced by Phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT.

Sirtuin family members selectively regulate autophagy in osteosarcoma and mesothelioma cells in response to cellular stress (2019)
Journal Article

The class III NAD+ dependent deacetylases-sirtuins (SIRTs) link transcriptional regulation to DNA damage response and reactive oxygen species generation thereby modulating a wide range of cellular signalling pathways. Here the contribution of SIRT1,... Read More about Sirtuin family members selectively regulate autophagy in osteosarcoma and mesothelioma cells in response to cellular stress.

What can independent research for Mesothelioma achieve to treat this orphan disease? (2019)
Journal Article
Guazzelli, A., Meysami, P., Bakker, E., Bonanni, E., Demonacos, C., Krstic- Demonacos, M., & Mutti, L. (2019). What can independent research for Mesothelioma achieve to treat this orphan disease?. Expert Opinion on Investigational Drugs, 28(8), 719-732. https://doi.org/10.1080/13543784.2019.1638363

Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with a poor prognosis, as current therapies are ineffective. Despite the increased understanding of the molecular biology of mesothelioma, there is still a lack of drugs that drama... Read More about What can independent research for Mesothelioma achieve to treat this orphan disease?.

BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment (2019)
Journal Article

Malignant mesothelioma (MMe) is a cancer with poor prognosis and resistance to standard treatments. Recent reports have highlighted the role of the BRCA associated protein 1 gene BAP1 in the development of MMe. In this study, the chemosensitivity of... Read More about BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment.

p53 modeling as a route to mesothelioma patients' stratification and novel therapeutic identification (2018)
Journal Article

Background: Malignant pleural mesothelioma (MPM) is an orphan disease that is difficult to treat using traditional chemotherapy, an approach which has been effective in other types of cancer. Most chemotherapeutics cause DNA damage leading to cell de... Read More about p53 modeling as a route to mesothelioma patients' stratification and novel therapeutic identification.

Insight into glucocorticoid receptor signalling through interactome model analysis (2017)
Journal Article
Bakker, E., Tian, K., Mutti, L., Demonacos, C., Schwartz, J., & Krstic-Demonacos, M. (2017). Insight into glucocorticoid receptor signalling through interactome model analysis. PLoS Computational Biology, 13(11), https://doi.org/10.1371/journal.pcbi.1005825

Glucocorticoid hormones (GCs) are used to treat a variety of diseases because of their potent anti-inflammatory effect and their ability to induce apoptosis in lymphoid malignancies through the glucocorticoid receptor (GR). Despite ongoing research,... Read More about Insight into glucocorticoid receptor signalling through interactome model analysis.

Immunotherapy advances for mesothelioma treatment (2017)
Journal Article

Introduction: Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ineffect... Read More about Immunotherapy advances for mesothelioma treatment.

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Tian, K., Demonacos, C., Krstic- Demonacos, M., & Mutti, L. (2017). Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opinion on Investigational Drugs, 26(8), 933-944. https://doi.org/10.1080/13543784.2017.1351545

Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to poor prognosis. Within... Read More about Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia (2017)
Journal Article

Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively. Mechanisms underlying ALL cell death and... Read More about Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma (2017)
Journal Article

Introduction: Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015–2030. Therapies remain ineffective, thus developing and testing novel treatments is important for both oncologists and researchers.


Areas co... Read More about Current and prospective pharmacotherapies for the treatment of pleural mesothelioma.

Anti-CTLA-4 therapy for malignant mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 9(3), 273-280. https://doi.org/10.2217/imt-2016-0123

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This... Read More about Anti-CTLA-4 therapy for malignant mesothelioma.